Summary. Islet A and B cells were purified from the rat pancreas and examined for their respective sensitivity to somatostatin. Both somatostatin-14 (S14) and -28 ($28) inhibited glucagon and insulin release through direct interactions with the corresponding cell types. A dose-dependent suppression of the secretory activities was paralleled by a reduction in cellular cyclic AMP formation with similar EDs0 values for both actions. The somatostatin effects on pancreatic hormone release may thus be mediated via an inhibition of adenylate cyclase activity. In pancreatic A cells, $14 and $28 were equally potent inhibitors with EDs0 values ranging from 2 • 10-12 to 2 x 10-i1 mol/1. Pancreatic B cells exhibited a similar sensitivity to $28 as the A cells (EDs0 of 2 to 5 x 10 -n tool/l), but not to $14 (ED50 of 2 x 10 -9 mol/1). Extrapolation of these in vitro sensitivities of islet A and B cells to the in vivo situation suggests that both cell types can respond to circulating $28 levels and that A cells are sensitive to both locally and distally released $14. Islet B cells appear insensitive to the normal peripheral $14 levels but could respond to locally released somatostatin. The marked difference in the sensitivities of islet A and B cells to $14 suggests that these cell types are equipped with different somatostatin receptors. This 
Somatostatin immunoreactive cells have been described in various sites of the body [1] [2] [3] [4] [5] [6] ; their hormonal products are synthesised as preprosomatostatin, a 12,000-14,000 dalton prohormone [7, 8] and released as somatostatin-28 ($28) or somatostatin-14 (S14) [9] [10] [11] [12] . The two latter peptides have been identified in the circulation and their administration in vivo and in vitro leads to the inhibition of a wide variety of physiologic processes [for review, see ref. 13]. In several cases, the specific action of each peptide could not be elucidated as it was difficult to distinguish direct from indirect interactions and to weigh the influence of the administered hormone versus that of the locally released one. In the endocrine pancreas, for example, addition of $14 or $28 leads to inhibition of insulin and glucagon release, with apparently differential effects of the two peptides [14] [15] [16] [17] . It remains, however, unknown whether the two somatostatins act directly and independently of each other on both pancreatic A and B cells, whether the somatostatin-induced effects on one cell type influence the secretory function of the other, and whether locally released somatostatin -originating from the islet D cells -participates in the final response. One way to clarify somewhat this complex issue consists in examining the effects of $14, of $28 and of related peptides on purified pancreatic A and B cells.
Materials and methods

Materials
Porcine glucagon was purchased from Novo Industries (Bagsvaerd, Denmark); $14 and its analogues, desAsnS[D-Trp s, D-Ser13]S14 and [D-Trp 8, D-Cys14]St4 were obtained from UCB Bioproducts (Braine L'Alleud, Belgium). The purity of the S14 analogues was higher than 98% on TLC and HPLC (UCB product information). $28 came from Sigma (StLouis, Mo, USA). The lyophilised peptides were dissolved in 2mol/l acetic acid supplemented with 0.25% (wt/vol) bovine serum albumin (BSA; Boehringer-Mannheim, Mannheim, FRG)o aliquoted and stored at -80 ~ The phosphodiesterase inhibitor Ro 20-1724 was kindly provided by Hoffman-La Roche (Basel, Switzerland). 1. 4 as to obtain the final experimental conditions for testing somatostatin (analogues). As it was the purpose to compare the inhibitory effects of the test substances, conditions were selected wherein the islet cells were stimulated through a synergistic interaction of nutrient-and ade-"~ nylcyclase-dependent regulatory units [22] [23] [24] [25] . Thus, pancreatic A cells were incubated at 1.4 mmol/1 glucose supplemented with a (3 mixture of amino acids (alanine, arginine and glutamine, 2 mmol/1 each) and noradrenaline (10 -`6 mol/1) [22, 24] , whereas pancreatic "~ B cells were examined at 20 mmol/1 glucose and 10 -8 tool/1 glucagon [23] [24] [25] . The somatostatin (analogues) were administered at vao.z rying concentration, immediately before start of the 15 min incubation at 37 ~ At the end of incubation, the tubes were centrifuged (1 min -250 g -4~ the supernatant fractions aspirated and analysed for their insulin or glucagon content and the cell pellets resus: pended in 0.5 ml 6% trichloroacetic acid (TCA) in order to extract cellular cyclic AMP [25] . The phosphodiesterase inhibitor Ro 20-1724 was added during the last 5 min of incubation in order to create the conditions for measuring the rate of cyclic AMP formation in parallel to the insulin or glucagon release. 
Insulin, glucagon and cyclic AMP assays
Cyclic AMP was measured as described previously [25] . The TCA supernatant fraction was extracted four times with 4 ml water-saturated diethylether, lyophilised, and redissolved in 0.05 mol/1 sodium acetate buffer (pH 6). 
Stat&tical analys&
Purification of pancreatic A and B cells
The techniques for the preparation of islet A and B cells have been described in full detail elsewhere [18] [19] [20] . Briefly, pancreatic islets were isolated from male adult Wistar rats using a modified collagenase technique [19] . The isolated islets were dissociated in calcium-free medium containing 1 mmol/1 ethyleneglycol-bis-(13-aminoethyl ether)N,N'-tetraacetic acid (EGTA), 25 ~tg/ml trypsin (BoehringerMannheim) and 2 lxg/ml DN-ase (Boehringer) [18] . The dissociated cells were separated by autofluorescence-activated cell sorting into pure A and pure B cell preparations [19, 20] . The isolated cells were reaggregated for 2 h in a rotatory shaking incubator (Braun, Melsungen, FRG) and then statically cultured for 20 h. The tissue culture medium was CMRL-1066 (GIBCO, Glasgow, UK) supplemented with 10% (vol/vol) heat-inactivated fetal calf serum (GIBCO), 2 mmol/l L-glutamine, penicillin (0.1 mg/ml) and streptomycin (0.1 mg/ml).
Incubations with $14, $28 and S14-analogues
At the end of 20 h culture, the A and B cell aggregates were collected from the petri dishes and washed with Earle's HEPES medium (EH) containing 1.4 mmol/1 glucose and 0.5% BSA. The composition of EH has been previously reported [19] . Cell viability as measured with neutral red [21] , exceeded 90% in all experiments. Groups of 5 x 104 cells were distributed as 0.1 ml samples over 5 ml plastic tubes (Falcon, Oxnard, Calif., USA) containing 1.4 ml EH. The ceils were allowed to sediment for 20 min, before 1 ml of supematant was carefully aspirated. The remaining 0.5 ml, containing the sedimented cell aggregates, was mixed with an additional volume of 0.5 ml composed Data represent mean values + SEM of at least four independent experiments. The statistical significance of differences between control and experimental conditions was calculated with two-tailed Student's t-tests. The acceptance level of significance (p<0.05) was corrected with the Bonferroni method in case of multiple comparisons [27] . EDs0 values were calculated with a logit approach based on normal distribution and least square regression analysis [28] and compared with a modified t-test [29] .
Results
Effect ofS14 and $28 on hormone release from pancreatic A and B cells
Both $14 and $28 exerted a potent inhibition on glucagon release induced by a mixture of amino acids and noradrenaline (Fig.l, left panel) . Their effect was already observed at 10-11 tool/1 (p< 0.05); complete suppression was obtained at 10 -9 mol/1. The two peptides were also inhibitory to insulin release induced by a mixture of glucose and glucagon (Fig. 1, fight panel) . This effect became statistically significant at 10 -n mol/1 for $28 (p<0.05) and at 10 -9 mol/1 for $14 (p< 0.001); maximal inhibition required concentrations of 10 -8 mol/1 for $28 and higher than 10 -7 mol/l for $14. Table 1 summarises the concentrations needed to obtain half-maximal inhibition (EDs0 values) for these Data represent mean values with corresponding 95% confidence intervals and were obtained after linear transformation of the sigmoid curves of Figure 3 using a logit approach based on normal distribution and least square regression analysis [28] . Significance of differences between estimated EDs0 values was assessed with a modified t-test [29] . A cells versus B cells: NS=not significant at p<0.05-$14 versus $28: a=not significant atp<0.05; b =significant atp<0.001
effects. For pancreatic A cells, the EDs0 values of $14 (10 -11 mol/1) and $28 (2 x 10 -11 mol/1) were not significantly different. With pancreatic B cells however, the ED50 value of $14 (2 x 10 -9 mol/1) was 40-fold higher than that of $28 (p< 0.001).
Effect ofS14 and $28 on cyclic AMPproduction in pancreatic A and B cells
Pancreatic A cells were suppressed in their noradrenaline-induced cyclic AMP production when exposed to $14 or $28 (Fig.2, left panel) . Inhibition occurred at 10-11 mol/1 (p < 0.05) and was complete at 10-10 mol/1. At 10 -11 mol/1, $14 was a more potent suppressor than S28 (p< 0.01). $14 and $28 also suppressed cyclic AMP production in pancreatic B cells stimulated by glucagon and glucose (Fig.2, right panel) . Significant inhibition was induced at 10 -11 mol/1 $28 (p<0.05) but required 1000-fold higher concentrations of $14. Complete suppression was achieved by 10 -9 mol/1 $28 and 10 -7 mol/1 $14. In the intermediate concentration range, $28 appeared a more powerful inhibitor than S14 (Fig. 2) .
The EDs0 values for the somatostatin inhibition of cAMP production in A cells were 2 x 10 -12 mol/1 with $14 and 8 x 10 -12 mol/1 with $28 (p> 0.05; Table 1 ). In pancreatic B cells, the EDs0 value of $14 (2 x 10 -9 mol/1) was 100-fold higher than that of $28 (p< 0.001; Table 1 ). The ED50 values for somatostatin-induced inhibition of hormone release were not significantly different from those for the inhibition of cAMP production in the corresponding conditions ( Table 1) .
Sensitivity of pancreatic A and B cells for $14 and $28
In order to compare the sensitivities of pancreatic A and B cells for $14 and $28, the respective effects of the peptides were expressed as a percent of the total suppressible activity, be it hormone release (Fig. 3 -left panels) or cyclic AMP production (Fig. 3 -right panels) . For somatostatin-14, it was noted that the process of hormone release and that of cAMP production could be suppressed in the picomolar range in the case of A cells but only in the nanomolar range in the case of pancreatic B cells (Fig. 3, top panels) . On the contrary, a similar sensitivity of A and B cells for somatostatin-28 was noted as the dose-response curves for this peptide could be superimposed ( Fig. 3 lower panels) . The EDs0 values for the inhibitory effects of $14 on hormone release and cAMP production were 200 to 1000-fold higher in pancreatic B cells than in pancreatic A cells (p< 0.001 - Table 1 ).
On the other hand, no significant difference was found in the EDs0 values of the $28 effects on both cell types.
Effect of somatostatin-14 analogues
In view of the observed difference in sensitivity of pancreatic A and B cells to somatostatin-14, we examined the cell-selectivity of two synthetic somatostatin-14 (Fig. 4) . When desAsnS[D-Trp s, D-Ser13]S14 was tested -even at a 10-fold higher concentration -it did not suppress glucagon release or cyclic AMP production in the A cell preparations (Fig. 4) , but reduced insulin release and cAMP production in pancreatic B cells (p<0.01) similar to equimolar S14 concentrations (Fig. 4) .
Discussion
The availability of purified pancreatic A and B cells permits to investigate in further detail the inhibitory action of somatostatin upon the endocrine pancreas [22, 23, 25] .
Our results confirm that somatostatin-14 can inhibit glucagon and insulin release via direct interactions with, respectively, A and B cells [22, 23] and extend this property to somatostatin-28. The inhibitory effects of S14 and $28 on hormone release were dose-dependent and closely parallelled by similar reductions in cyclic AMP formation as indicated by the respective EDs0 values. A reduced adenylcyclase activity may thus mediate -at least in part -the inhibitory effect of soma- The statistical significance of differences between conditions with somatostatin analogues and control was calculated with the unpaired Student's t-test and was corrected with the Bonferroni method for multiple comparisons [27] . *: p<0.01 versus control tostatin on pancreatic hormone release [22, 25] . Somatostatin also suppresses cyclic AMP production in other cell types [30] [31] [32] . Its ability to inhibit glucagon or insulin release may thus depend on the degree to which these processes are activated by the adenylcyclase unit at the time of exposure. The possibility nevertheless remains that somatostatin is also capable of influencing the hormone release process via additional, cyclic AMP-independent, routes [33, 34] . The pancreatic A cells were inhibited by low somatostatin concentrations (EDs0 values between 2 x 10-12 tool/1 and 2 x 10 -11 mol/1). These levels can be considered as physiologic even if pancreatic somatostafin has no direct access to the neighbouring A cells. Plasma somatostatin levels vary between 10-t2mol/1 and 5 x 10 -~1 mol/1 [35] and may thus influence the rate of glucagon release in vivo. Since $14 seems -in this concentration range -a more potent inhibitor than $28, it is conceivable that the relative proportions of both forms will further modulate the degree of inhibition.
Pancreatic B' , cells were only suppressed by $14 concentrations of 10 -9 mol/1 or higher. This relatively low sensitivity to the exogenous hormone should not be attributed to the presence of endogenously released $14 as the purified B cell preparation contains less than 3 percent D-cells [19] and as the endogenous somatostatin levels measured in the controls were lower than 10 -11 mol/1 [22] . It is also unlikely that it is caused by damage during tissue dissociation since pancreatic A cells -which were exposed to the same procedure as the B cells -exhibited an exquisite responsiveness to $14. Moreover, the isolated B cells have been previously shown to exhibit high affinity binding sites for other peptides [26, 36] , and were found, in this paper, to be sensitive to concentrations of $28 in the picomolar range, a sensitivity which is similar to that previously noted in intact pancreata [16, 17] . When extrapolated to the in vivo situation, these data suggest that the regulation of insulin release by somatostatin-14 is only conceivable if pancreatic somatostatin reaches the islet B cells before it is diluted in the general circulation. It is still unclear whether such direct access exists via the intercellular space or via the local circulation. According to Bonner-Weir and Orci [37] and Kawai et al. [38] , the intra-islet vascularisation does not permit an influence via the local circulation. The fact that purified B cells were nearly 50-fold more sensitive to $28 (Table 1) , suggests a regulatory role for circulating $28, which mainly originates from the gastrointestinal tract.
A comparison of the EDs0 values indicates that $14 is approximately 500-fold more potent in pancreatic A cells than in B cells. This difference in biological activity may result from the existence of two different somatostatin receptors, i.e. high affinity $14 receptors on A cells and low affinity binding sites for $14 on B cells. The results obtained with $14 analogues support this view, as one analogue acted preferentially on A cellsreproducing the marked suppressive effects of $14 -whereas the other remained without effect on A cells but induced a modest inhibition in B cells. The in vitro findings with these drugs are in good agreement with previous in vivo observations [39] [40] [41] . The physiologic meaning of the different sensitivity of pancreatic A and B cells to $14 is still unclear. It may represent another example of the divergent regulation which can be expected for the release of counteracting hormones [24] . The respective hormone responses thus become dependent on the origin and the extent of the increased $14 levels. Locally, this different sensitivity to $14 may be part of a functional integration of the various islet cell types. On the other hand, the EDs0 values for the suppressive effects of $28 indicate that both cell types are highly and equally sensitive to this peptide. Pancreatic A and B cells seem therefore to be equipped with high affinity $28 receptors.
The similarity in $28 sensitivity and the difference in $14 sensitivity suggest that the putative somatostatin receptor on A cells is to be distinguished from that on B cells. Cell-selective binding of $14 and $28 has also been suggested on the basis of autoradiographic studies in unpurified rat islet cell monolayers [42] . Binding studies with intact purified A and B cells are of course necessary to further document the existence of different somatostatin receptors on both cell types. These experiments will also tell whether the high affinity $28 receptors on B cells provide low affinity binding sites for $14.
